Browse the evidence

Diet-induced changes in endogenous gut-derived appetite hormones (GLP-1, GIP, PYY, ghrelin) do not reliably predict or control ad libitum energy intake in humans.

Do not rely on macronutrient manipulation (like Keto or Low-Fat) to regulate your appetite through hormones. This study proves that even when hormones change significantly, they do not predict how much you will eat. Instead, focus on food properties: lower energy density and fewer hyper-palatable combinations (fat/sugar/sodium) are more effective for controlling intake than hormone-targeting diets.

Endogenous gut hormone concentrations achieved through dietary changes are orders of magnitude lower than pharmacological doses, explaining why diet fails to suppress appetite while drugs succeed.

You cannot replicate the effects of GLP-1 drugs (like Ozempic) through diet alone because the hormonal concentrations achieved by eating are too low. Diet changes affect hormones, but not enough to significantly reduce appetite or energy intake.

Genetic loss-of-function variants of the GIP receptor are associated with lower body mass index (BMI) and reduced obesity prevalence in humans.

People with certain genetic variations that reduce GIP receptor function tend to have lower body weight. This genetic insight supports the development of drugs that block GIP receptors to achieve similar weight loss benefits.

Semaglutide increases the risk of non-serious gastrointestinal adverse events, specifically nausea, vomiting, and diarrhea, in patients at increased risk of cardiovascular events.

Expect stomach issues like nausea, vomiting, or diarrhea when starting semaglutide. These are common, usually get better over time, and are not considered 'serious' adverse events. Managing diet and starting with a low dose can help mitigate these effects.

High-dose tirzepatide (15mg/week) is associated with a significantly increased risk of overall gynecologic tumors compared to controls, with an odds ratio of 2.37.

If you are taking high-dose tirzepatide (15mg/week), be aware that this network meta-analysis found a statistically significant increase in gynecologic tumor risk compared to controls. The absolute risk increase is small (0.57%), but it exists. Discuss this with your doctor to weigh the metabolic benefits against this potential risk, especially if you have other predisposing factors for gynecologic cancers.

Both high-dose (15mg/week) and low-dose (5mg/week) tirzepatide are associated with a significantly elevated risk of intra-uterus tumors.

If you are taking tirzepatide (whether 5mg or 15mg weekly), be aware that this network meta-analysis found a statistically significant increase in the risk of intra-uterus tumors. The risk appears to be present at both low and high doses. Discuss this with your doctor to weigh the metabolic benefits against this potential risk, especially if you have other predisposing factors for gynecologic cancers.

Tirzepatide reduces the incidence of heart failure hospitalizations, need for treatment intensification, and mortality due to cardiovascular causes in patients with heart failure and reduced ejection fraction.

If you have heart failure and reduced ejection fraction, Tirzepatide can reduce your risk of hospitalization and cardiovascular mortality.

Obeticholic acid reduces liver fibrosis but does not resolve NASH, and is associated with significant side effects like pruritus and increased LDL.

Obeticholic acid can reduce liver scarring (fibrosis) but does not cure the underlying inflammation (NASH). It causes itching in over 50% of patients at higher doses and raises LDL cholesterol, which may need to be managed with statins. It is not a first-line cure.

Initiation of GLP-1 receptor agonists (GLP-1RA) in older adults with type 2 diabetes on stable levothyroxine therapy significantly increases the risk of new-onset atrial fibrillation or flutter (AF/Aflutter) compared to SGLT2 inhibitors.

If you take levothyroxine and start a GLP-1RA (like Ozempic or Wegovy), your thyroid hormone levels may become too high because you lose weight or absorb the medication differently. This increases your risk of irregular heartbeats (AF). You need closer monitoring of your TSH levels and likely a reduction in your levothyroxine dose shortly after starting the GLP-1RA to prevent this.

GLP-1 receptor agonists (exenatide, liraglutide, dulaglutide, semaglutide, tirzepatide) reduce hepatic lipid accumulation in MASLD patients, primarily through indirect mechanisms involving weight loss and reduced fatty acid deposition, and directly by improving insulin sensitivity and suppressing de novo lipogenesis.

GLP-1 agonists like semaglutide and tirzepatide are effective treatments for reducing liver fat in people with MASLD, especially if they also have type 2 diabetes or obesity. They work by improving insulin sensitivity and directly reducing fat production in the liver, in addition to helping with weight loss. While they significantly reduce liver fat, they may not reverse advanced scarring (fibrosis). Consistency is key, as side effects and cost can lead to stopping treatment.

GLP-1 receptor agonists have limited efficacy in reversing advanced hepatic fibrosis compared to their ability to reduce hepatic steatosis.

If you have advanced liver scarring (fibrosis), GLP-1 medications may not reverse it, even though they will likely reduce liver fat. Newer multi-agonists (like resmetirom or dual agonists) might be needed for fibrosis.

Retatrutide increases the incidence of adverse events, particularly nausea, vomiting, and decreased appetite, in a dose-dependent manner compared to placebo.

While effective, retatrutide causes more side effects than placebo, including nausea, vomiting, and constipation. These side effects increase with higher doses (8mg and 12mg). Patients should be prepared for these potential issues, which may affect adherence.

Genetic factors significantly predispose individuals to obesity, with heritability estimates exceeding 70% for fat difference, involving genes like LEP, LEPR, and MC4R.

If you have a family history of obesity, be aware that your body may fight weight loss more strongly. Focus on consistent, sustainable habits rather than quick fixes, and consider seeking professional guidance to navigate biological challenges.

Senescent cells secrete a complex, heterogeneous proteome (SASP) that includes specific proteins (GDF15, STC1, SERPINs) which correlate with human aging and serve as potential plasma biomarkers for cellular senescence burden.

This research identifies specific proteins (GDF15, STC1, SERPINs) secreted by senescent cells that correlate with aging in human blood. While not yet a commercial test, these markers offer a potential way to measure 'senescent burden' in the future, linking cellular aging to systemic health.

SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin) improve glycemic control in type 2 diabetes by blocking glucose reabsorption in the renal proximal tubule, inducing glycosuria.

If you have Type 2 Diabetes and your kidneys are functioning adequately (eGFR > 30), SGLT2 inhibitors like empagliflozin or dapagliflozin can help lower your blood sugar by causing your kidneys to excrete glucose in your urine. This is done via a daily oral pill. While there is a risk of genital infections, they are generally mild and manageable. The key benefit is that these drugs also offer cardiovascular and renal protection beyond just lowering blood sugar.

Once-weekly subcutaneous dulaglutide (1.5 mg) is administered to patients with type 2 diabetes to evaluate its effect on cardiovascular outcomes, including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.

This paper outlines the design of the REWIND trial, which tests whether once-weekly dulaglutide (1.5 mg) reduces cardiovascular events (heart attack, stroke, cardiovascular death) in people with type 2 diabetes who are at high risk. The trial includes nearly 10,000 participants with a mean age of 66, many of whom have prior cardiovascular disease or risk factors. The results of this trial will help determine if dulaglutide is an effective cardiovascular protective agent for this population.

Intramuscular androgen receptor content, rather than systemic or intramuscular hormone levels, determines the magnitude of resistance training-induced skeletal muscle hypertrophy in healthy, young men.

If you are a healthy, young man who already lifts weights regularly, your muscle growth potential is likely determined by your genetic muscle receptor density, not your blood testosterone levels. You cannot change your receptor density with supplements or TRT if your levels are already normal. Focus on consistent, progressive resistance training rather than trying to manipulate hormones.

Obesity pathophysiology is driven by complex interactions between genetic susceptibility, environmental factors, and hormonal signaling (leptin, insulin, ghrelin, GLP-1) that regulate energy balance, rather than simple caloric imbalance alone.

Obesity is not just a failure of willpower; it involves complex hormonal signals (like leptin and insulin) and genetics. Effective management often requires addressing these biological drivers, potentially through lifestyle changes combined with medical therapies that target these specific pathways.

High body mass index (BMI) is a strong independent risk factor for the development and progression of Chronic Kidney Disease (CKD), primarily driven by compensatory glomerular hyperfiltration and increased intraglomerular pressure.

Maintaining a healthy weight is one of the most effective ways to protect your kidneys. Excess body weight forces your kidneys to work harder (hyperfiltration), which can cause long-term damage. While weight loss is complex in advanced kidney disease, preventing obesity is a primary strategy for avoiding kidney failure.

Semaglutide 2.4 mg once weekly does not increase the risk of developing symptoms of depression or suicidal ideation/behavior compared to placebo in people with overweight or obesity without known major psychopathology.

If you are considering semaglutide for weight loss and are worried about your mental health, know that large clinical trials show it does not increase the risk of depression or suicidal thoughts compared to a placebo. While you should still monitor your mood as recommended, the medication itself is not causing these psychiatric issues. This is particularly reassuring if you have no history of major mental health conditions.

Obesity directly causes chronic kidney disease (CKD) and end-stage renal disease (ESRD) through compensatory hyperfiltration, glomerular hypertension, and adipose-derived inflammatory mediators, independent of diabetes and hypertension.

Maintaining a healthy body weight is critical for kidney health. Obesity increases pressure inside the kidney's filtering units (glomeruli) and releases hormones that cause inflammation and scarring, leading to chronic kidney disease. This risk exists even if you do not have diabetes or high blood pressure. Preventing obesity through lifestyle changes is the most effective way to protect your kidneys.

GLP-1 RAs can cause clinically significant drug-drug interactions (DDIs) by delaying gastric emptying, particularly affecting the absorption of oral contraceptives and levothyroxine.

If you take oral contraceptives or levothyroxine, be aware that GLP-1 drugs can change how well these work by slowing stomach emptying. Your doctor may need to monitor your levels or adjust doses. Use backup contraception if advised.

Integrase strand transfer inhibitors (INSTIs), particularly dolutegravir and bictegravir, are the primary drivers of weight gain in modern ART regimens, with effects observed as early as 4 weeks post-initiation.

If you are taking an INSTI (like dolutegravir or bictegravir), be aware that these drugs are strongly linked to weight gain, often starting within weeks of taking them. This is a known side effect of the drug class, not just your lifestyle. If you are at high risk (e.g., woman, Black patient), discuss your concerns with your doctor. They might consider alternative regimens, though these may have other trade-offs.

GLP-1 receptor activation suppresses glucagon secretion primarily through an indirect mechanism involving somatostatin release from delta-cells, rather than direct action on alpha-cells.

GLP-1 drugs help control blood sugar not just by boosting insulin, but by suppressing glucagon (a hormone that raises blood sugar). This suppression happens indirectly by stimulating other cells (delta-cells) to release somatostatin, which then inhibits glucagon. This dual action makes GLP-1 drugs effective for lowering blood glucose.